Industry News

Pharmaceutical Industry News

Akeso and Summit’s ivonescimab…

September 9th, 2026|Fierce Pharma|

Akeso and Summit’s ivonescimab reduced the risk of death by 27% compared with Keytruda in the phase 3 Harmoni-2 trial in first-line, PD-L1-positive non-small cell lung cancer, with particularly strong data in the PD-L1-high group.

Bayer has won first-line approval…

September 9th, 2026|Fierce Pharma|

Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med

The 60-second ad sees…

September 9th, 2026|Fierce Pharma|

The 60-second ad sees "Yellowstone" actor Kevin Costner doing the math on the benefits of early cancer detection with Caris' Caris Detect blood test.

With a phase 3 win now fleshed out…

September 9th, 2026|Fierce Pharma|

With a phase 3 win now fleshed out and an FDA filing recently submitted, BioMarin is advancing expansion plans for Voxzogo, looking to extend the dwarfism drug’s reach as it faces new pressure in its

Merck continues sweeping staff…

September 9th, 2026|Fierce Pharma|

Merck continues sweeping staff reductions, laying off 54 at its Rahway headquarters. The staff changes are set to take effect in December and January.

As drug discovery is…

September 9th, 2026|Fierce Pharma|

As drug discovery is revolutionized by AI, the machinery built to get life-saving medicines to market remains trapped in a different era. Here’s how we solve that.

In a stabilizing move, the…

September 9th, 2026|Fierce Pharma|

In a stabilizing move, the Department of Health and Human Services announced Tuesday afternoon that it has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of CDER and CBER, respectively—to

Exclusive insights from the…

September 8th, 2026|Fierce Pharma|

Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and patient-focused drug development.

Spying a “golden decade”…

September 8th, 2026|Fierce Pharma|

Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar capabilities in the coming years.

While Amgen gave no numerical…

September 8th, 2026|Fierce Pharma|

While Amgen gave no numerical results from Imdelltra's latest overall survival win in first-line small cell lung cancer, R&D chief Jay Bradner said data suggest the DLL3 bispecific “will further revolutionize the standard for survival

Shifts in drug pricing and market…

September 8th, 2026|Fierce Pharma|

Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for years to come, a survey of industry leaders found.

Novo Nordisk has reported a phase…

September 8th, 2026|Fierce Pharma|

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer classified as having obesity after receiving the GLP-1 drug for 68 weeks.

In a rare divergence from its own…

September 8th, 2026|Fierce Pharma|

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new treatment paradigm for molecular-guided

Roche has retained its status as…

September 8th, 2026|Fierce Pharma|

Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate reputation rankings.

Belgian biopharma UCB is seeking…

September 8th, 2026|Fierce Pharma|

Belgian biopharma UCB is seeking to boost awareness of what epilepsy looks like to patients, literally, with a new campaign using art to tell their stories.